NCT04692324Recruiting
Cerebrospinal Fluid Biomarkers for Brain Tumors
Source: ClinicalTrials.gov · Last updated 22 Apr 2026
Brief summary (registry, in English)
This study examines cerebrospinal biomarkers in patients with brain tumors. A biomarker is a measurable indicator of the severity or presence of your disease state. Collecting and storing samples of cerebrospinal fluid from patients with brain tumors to study in the laboratory may help doctors develop new strategies to better diagnose, monitor, and treat brain tumors.
- Status (registry)
- Recruiting
- Study type
- Observational
- Enrollment
- 400 (estimated)
- First submitted
- 29 Dec 2020
- Start date
- 14 Jan 2021
- Primary completion date
- 31 Dec 2028
- Lead sponsor
- Mayo Clinic
- Diseases
- Childhood cancers
- NCT number
- NCT04692324
What you commit to
- Study type: Observational
- Planned participants: 400
- From 14 Jan 2021 to the primary completion date, 31 Dec 2028
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Age
- Patients who are under 18 years of age or are a member of a vulnerable population will be excluded from this study
Other
- Pregnant women or women who may be pregnant are specifically excluded from study participation
- Exception will be granted for patients with diminished capacity to consent if a legally authorized representative is available
- Patients without clinical or radiographic evidence of a potentially neoplastic CNS lesion will be excluded
- Patients with an inability or unwillingness of individual or legal guardian/representative to give written informed consent will be excluded
- Any patient for whom a clinical contraindication exists to the intended route of CSF access will be excluded. For example, a patient with a large posterior fossa mass lesion at risk of herniation, or a patient with coagulopathy, or other contraindication to lumbar puncture would not be eligible to participate via use of lumbar puncture for CSF access
Who the study is looking for
- Any evidence of neoplasm involving the central nervous system (CNS) or its adjacent structures in contact with CSF. Such lesions may include but are not limited to intra-axial or extra-axial lesions, which could be benign, malignant or as yet undefined, involving the brain, spine, meninges, nerves, or vasculature or supporting structures
- Subjects must be 18 years of age or older
Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Mayo Clinic in Rochester Coordinator of this site? Confirm its status | Rochester | United States | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.